A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
Clin Transl Oncol
; 22(9): 1565-1579, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32062835
ABSTRACT
BACKGROUND:
This article describes and compares approved targeted therapies and the newer immunotherapy agents. MATERIALS ANDMETHODS:
This article especially performs an in-depth review of currently available data for tivozanib, explaining its mechanism of action, its safety profile and its role as an efficacy drug in the management of renal cancer.RESULTS:
Despite the fact that the treatment of advanced RCC has been dramatically modified in recent years, durable remissions are scarce and it remains a lethal disease. For first- and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment.CONCLUSIONS:
Several TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Quinolinas
/
Carcinoma de Células Renais
/
Receptores de Fatores de Crescimento do Endotélio Vascular
/
Inibidores de Proteínas Quinases
/
Neoplasias Renais
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Espanha